Statute Details
- Title: National Registry of Diseases (Specified Entity for Acute Myocardial Infarction) Notification 2012
- Act Code: NRDA2007-S412-2012
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: National Registry of Diseases Act (Cap. 201B)
- Enacting Authority: Minister for Health
- Key Enabling Provision: Section 24(2) of the National Registry of Diseases Act
- Commencement: 1 September 2012
- Primary Subject Matter: Designation of a “specified entity” for collection of information relating to acute myocardial infarction
- Current Version Status: Current version as at 27 March 2026 (per the provided extract)
- Legislative Instrument Number: S 412/2012
What Is This Legislation About?
The National Registry of Diseases (Specified Entity for Acute Myocardial Infarction) Notification 2012 is a short but important piece of subsidiary legislation that designates an organisation responsible for collecting information about a specific medical condition—acute myocardial infarction (commonly known as a heart attack).
In plain terms, the Notification answers a practical administrative question: which body is authorised (as a “specified entity”) to collect information relating to acute myocardial infarction for the purposes of the National Registry of Diseases framework. This designation matters because disease registries typically involve sensitive health data and require clear legal authority for collection and handling.
The Notification is made under the National Registry of Diseases Act (Cap. 201B). It does not create a new registry by itself; rather, it operates within an existing statutory scheme by identifying the specific entity that will perform the relevant data collection function for this particular disease.
What Are the Key Provisions?
Section 1: Citation and commencement. This provision sets the legal identity of the instrument and when it takes effect. The Notification may be cited as the National Registry of Diseases (Specified Entity for Acute Myocardial Infarction) Notification 2012 and comes into operation on 1 September 2012. For practitioners, commencement is critical when assessing whether a particular collection of data occurred under the authority of the Notification.
Section 2: Specified entity for acute myocardial infarction. This is the substantive provision. It declares that the National Registry of Diseases Office of the Health Promotion Board (established under the Health Promotion Board Act (Cap. 122B)) is the specified entity for the collection of information relating to acute myocardial infarction for the purposes of section 24 of the National Registry of Diseases Act.
Although the extract is brief, the legal effect is significant. By naming the specified entity, the Minister for Health authorises (within the statutory framework) that particular office to collect information relating to acute myocardial infarction. The phrase “for the purposes of section 24 of the Act” indicates that section 24 of the National Registry of Diseases Act sets out the statutory mechanism for designating entities and the legal consequences of being designated.
Practical implications of “specified entity” designation. In registry legislation, the designation of a specified entity typically determines who may lawfully receive, compile, and manage disease-related information. It also affects how other stakeholders (such as healthcare institutions, clinicians, or data providers) interact with the registry system. Even where the Notification does not detail procedures, it provides the legal anchor for the registry office’s role in relation to acute myocardial infarction.
How Is This Legislation Structured?
This Notification is structured as a concise instrument with an enacting formula and two operative sections.
Enacting formula: It states that the Minister for Health makes the Notification in exercise of powers conferred by section 24(2) of the National Registry of Diseases Act. This is a standard legislative drafting approach that links the Notification’s authority to the enabling provision.
Section 1 (Citation and commencement): Provides the name and effective date.
Section 2 (Specified entity for acute myocardial infarction): Performs the designation function by identifying the National Registry of Diseases Office of the Health Promotion Board as the specified entity for this disease.
Notably, the extract shows no additional parts, schedules, reporting requirements, or procedural rules within the Notification itself. Those details are expected to be found in the parent Act (the National Registry of Diseases Act) and possibly in other related subsidiary instruments or administrative guidance.
Who Does This Legislation Apply To?
The Notification primarily applies to the specified entity it designates—namely, the National Registry of Diseases Office of the Health Promotion Board. The legal effect is directed at the entity’s role in collecting information relating to acute myocardial infarction under the National Registry of Diseases Act.
However, the designation also has downstream implications for data flows within the healthcare system. While the Notification itself does not list hospitals, laboratories, or clinicians, in practice those parties may be involved in providing information to the registry system. For a practitioner, the key point is that the Notification supplies the legal basis for the registry office’s collection function for this specific condition, which may influence compliance obligations and data governance arrangements across the ecosystem.
Why Is This Legislation Important?
Even though the Notification is brief, it is legally consequential because it clarifies who is empowered to collect information for a disease registry purpose. In health data regulation, clarity of authority is essential: without a proper designation, collection and processing of sensitive health information may be vulnerable to legal challenge or may fall outside the intended statutory permissions.
From a compliance perspective, the designation of the Health Promotion Board’s National Registry of Diseases Office as the specified entity for acute myocardial infarction helps organisations understand where they should direct relevant information and which body is responsible for registry-related data handling. This reduces uncertainty and supports consistent implementation of the national registry framework.
From a governance and risk management perspective, the Notification also signals that acute myocardial infarction is within the scope of the National Registry of Diseases Act’s disease-specific collection regime. Practitioners advising hospitals, healthcare groups, or health data controllers should treat such designations as part of the legal landscape governing health information. They may affect internal policies on consent, disclosure, data minimisation, retention, security controls, and audit trails—particularly where data is shared with or processed by the specified entity.
Related Legislation
- National Registry of Diseases Act (Cap. 201B) — the authorising Act, including section 24(2) (enabling the Minister to designate specified entities) and the broader statutory framework for the registry.
- Health Promotion Board Act (Cap. 122B) — establishes the Health Promotion Board, under which the National Registry of Diseases Office is established.
Source Documents
This article provides an overview of the National Registry of Diseases (Specified Entity for Acute Myocardial Infarction) Notification 2012 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.